title: Differential expression of the alpha2 chain of the interleukin-13 receptor in metastatic human prostate cancer ARCaPM cells.
abstract: BACKGROUND
  The alpha2 chain of the interleukin-13 receptor (IL13Ralpha2) is a high-affinity receptor and a candidate target for cytotoxic killing of cancer cells. Availability of a human prostate cancer cell line with high level of IL13Ralpha2 expression will facilitate the development of therapeutic modalities.
  
  
  METHODS
  ARCaP(E) and ARCaP(M) human prostate cancer cell lines were subjected to comparative analyses of gene expression. Expression of the IL13Ralpha2 protein was confirmed by Western blotting and immunostaining. IL13Ralpha2 proteins in xenograft tumors and clinical human prostate cancer specimens were detected by specific antibodies. LNCaP prostate cancer cells stably transfected with IL13Ralpha2 were examined for accelerated growth in athymic mice.
  
  
  RESULTS
  We found that IL13Ralpha2 proteins could be detected in both the ARCaP(E) and ARCaP(M) cells, but the expression level in ARCaP(M) was more than 17-fold higher than in ARCaP(E) cells. Importantly, the ARCaP lineage represented the only human prostate cancer cell line that expresses IL13Ralpha2 proteins at the level detectable by Western blotting. Expression of IL13Ralpha2 was accompanied by resistance to the anti-tumor activity of interleukin-13 (IL-13). ARCaP cells were found to be insensitive to growth inhibition upon IL-13 treatment, while overexpression of IL13Ralpha2 in LNCaP cells promoted intratibial tumor growth in athymic mice.
  
  
  CONCLUSIONS
  Differential IL13Ralpha2 expression may account for the high tumorigenic and metastatic potential of ARCaP(M) cells. The unique expression of IL13Ralpha2 makes ARCaP lineage an attractive model for evaluating the targeting efficacy of therapeutic agents based on IL13Ralpha2 protein expression.
authors.affiliation: Department of Urology, the First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
authors.forename: Hui
authors.initials: H
authors.lastname: He
authors.forename: Jianchun
authors.initials: J
authors.lastname: Xu
authors.forename: Peter S
authors.initials: PS
authors.lastname: Nelson
authors.forename: Fray F
authors.initials: FF
authors.lastname: Marshall
authors.forename: Leland W K
authors.initials: LW
authors.lastname: Chung
authors.forename: Haiyen E
authors.initials: HE
authors.lastname: Zhau
authors.forename: Dalin
authors.initials: D
authors.lastname: He
authors.forename: Ruoxiang
authors.initials: R
authors.lastname: Wang
mesh_terms: D000818:Animals; D015153:Blotting, Western; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D002478:Cells, Cultured; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics; D006801:Humans; D007150:Immunohistochemistry; D018793:Interleukin-13 / Q000235:genetics / Q000378:metabolism* / Q000494:pharmacology; D053663:Interleukin-13 Receptor alpha2 Subunit / Q000235:genetics* / Q000378:metabolism; D008297:Male; D051379:Mice; D008819:Mice, Nude; D011467:Prostate / Q000187:drug effects / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014162:Transfection; D014183:Transplantation, Heterologous
chemical_list: D018793:Interleukin-13; D053663:Interleukin-13 Receptor alpha2 Subunit